• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amarin Corp ADR (NQ: AMRN )

    0.6371 +0.0085 (+1.35%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 319,920
    Open 0.6383
    Bid (Size) 0.6250 (1)
    Ask (Size) 0.6500 (40)
    Prev. Close 0.6286
    Today's Range 0.6220 - 0.6383
    52wk Range 0.5701 - 1.370
    Shares Outstanding 407,265,944
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
    AMRN earnings call for the period ending June 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial

    Performance

    YTD
    -28.35%
    -28.35%
    1 Month
    -18.32%
    -18.32%
    3 Month
    -24.17%
    -24.17%
    6 Month
    -47.35%
    -47.35%
    1 Year
    -38.74%
    -38.74%

    More News

    Read More
    Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Amarin Corporation plc
    Via GlobeNewswire
    3 Breakthrough Stocks Under $10 Set for Massive Upside
    Via InvestorPlace
    Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
    From Amarin Corporation plc
    Via GlobeNewswire
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Via Investor's Business Daily
    Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Amarin Board of Directors Announces CEO Transition
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Amarin Corporation plc
    Via GlobeNewswire
    AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Amarin Reports First Quarter 2024 Business Update and Financial Results
    From Amarin Corporation plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Announces Results of Annual General Meeting of Shareholders
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
    From Amarin Corporation plc
    Via GlobeNewswire
    New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
    From Amarin Corporation plc
    Via GlobeNewswire
    Why Amarin Stock Was Rocketing Higher on Wednesday
    Via The Motley Fool
    Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
    From Amarin Corporation plc
    Via GlobeNewswire
    Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
    From Amarin Corporation plc
    Via GlobeNewswire
    Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.